Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page
- Check3 days agoChange DetectedA notification banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check10 days agoChange DetectedThe revision label in the footer changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check17 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0; the study page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe page now renders a 403 Forbidden error, replacing the study content with a simple error layout and a Home button. The detailed study information and navigation are no longer visible due to access restrictions.SummaryDifference16%

- Check45 days agoChange DetectedThe study record now includes information about sharing individual participant data (IPD), including policy details, the plan for IPD sharing, and a URL for the policy.SummaryDifference0.4%

- Check59 days agoChange DetectedA funding line for 2019 (U.S. NIH Grant/Contract) has been added. The revision history now shows Revision: v3.6.6, replacing the previous v3.6.5 entry.SummaryDifference0.0%

Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.